TG THERAPEUTICS, INC. (TGTX) Stock
9 of the hedge funds AlphaScala tracks reported TGTX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is D.E. Shaw's at $186.84M. Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own TGTX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 3.40M | $186.84M | +476% |
| Renaissance Technologies Jim Simons (founder) | 679K | $37.32M | +99% |
| Citadel Ken Griffin | 537K | $29.51M | -72% |
| Bridgewater Associates Ray Dalio | 430K | $23.62M | +38% |
| Millennium Management Israel Englander | 273K | $14.97M | +122% |
| Point72 Steve Cohen | 265K | $14.56M | NEW |
| Hussman Investment Trust John Hussman | 53K | $2.88M | NEW |
| Blackstone | 7K | $406.8K | NEW |
| Marshall Wace | 6K | $316.3K | -78% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are TG THERAPEUTICS, INC. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 10, 26 | Charney Laurence N | Director | SELL | 5.0K | $275K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →TGTX price chart
Powered by TradingViewWhat does TG THERAPEUTICS, INC. do?
TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases, including malignancies and autoimmune disorders, in the United States and internationally. Its lead product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), encompassing clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The company advances a pipeline featuring TG-1701, an orally available covalent Bruton's tyrosine kinase (BTK) inhibitor selective for BTK; TG-1801, a bispecific CD47 and CD19 antibody; and azer-cel, an allogeneic CD19 CAR T therapy, all targeting B-cell disorders and currently in early clinical stages. TG Therapeutics, Inc. generates revenue primarily from BRIUMVI net product sales in the U.S., with additional contributions from international partners. Founded in 1993 and headquartered in Morrisville, North Carolina, it plays a key role in addressing unmet needs in neurology and oncology through targeted immunotherapies.